Milestone supports advancement of PRF’s drop-less ocular drug-delivery platform into next-stage U.S. clinical development for post-cataract pain and inflammationTEL AVIV, Israel, April 28, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) (“PRF” or the “Company”), a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics for post-operative pain management, together with its majority-owned subsidiary LayerBio, Inc., today announced that the U.S. Food and ...